Get the tools used by (smart)2 investors.

Roche Holding AG ParticipationLSE:0QOK

Switzerland / Healthcare / Pharmaceuticals

Income Statement
Balance Sheet
Cash Flow Statement
EBITDA Reconciliation
Net Income Reconciliation
Forecasts
Valuation Ratios
Fiscal Years
Fiscal Half
Fiscal Quarters
Year To Date
Latest Twelve Months
Ascending
Descending
3 Years
5 Years
10 Years
Millions
Billions
Thousands
Ones
Standard Size
Common Size
Growth Rate
2020-12-31
FY-4
2021-12-31
FY-3
2022-12-31
FY-2
2023-12-31
FY-1
2024-12-31
FY
Revenue
-
-
58.8
359.7
407.6
Revenue Growth (YoY)
NM
NM
NM
525.1%
4.4%
Cost of Revenues
0.0
0.0
-32.5
-179.9
-210.3
Gross Profit
-
-
26.3
179.8
197.3
Gross Profit Margin
-
-
44.7%
50.0%
48.4%
R&D Expenses
0.0
0.0
0.0
0.0
0.0
Selling and Marketing Expense
0.0
0.0
0.0
0.0
0.0
General & Admin Expenses
-3.9
-6.2
-7.4
-9.7
-13.2
Other Inc / (Exp)
-20.6
-17.7
-14.2
-68.4
-44.6
Operating Expenses
-24.5
-23.9
-21.6
-78.1
-57.8
Operating Income
-24.5
-23.9
4.7
101.7
139.5
Net Interest Expenses
0.2
0.2
-2.1
-18.5
-17.4
EBT, Incl. Unusual Items
-24.3
-23.7
2.6
83.3
122.0
Earnings of Discontinued Ops.
-
-
-
-
-
Income Tax Expense
0.0
0.0
0.0
-17.5
-29.9
Net Income to Company
-24.3
-23.7
2.6
65.7
92.1
Minority Interest in Earnings
1.9
0.2
-1.3
-8.6
-12.0
Net Income to Stockholders
-22.5
-23.5
1.3
57.2
80.1
Preferred Dividends & Other Adj.
0.0
0.0
0.0
0.0
0.0
Net Income to Common Excl Extra Items
-22.5
-23.5
1.3
57.2
80.1
Basic EPS (Cont. Ops)
-0.090
-0.074
0.0038
0.16
0.20
Diluted EPS (Cont. Ops)
-0.090
-0.076
0.0036
0.16
0.19
Weighted Average Basic Shares Out.
248.7
317.9
329.9
358.2
407.1
Weighted Average Diluted Shares Out.
248.7
317.9
346.6
368.3
414.3
EBITDA
-23.6
-10.7
5.4
159.2
177.1
EBIT
-24.6
-10.9
1.7
119.7
136.1
Revenue (Reported)
-
-
58.8
359.7
407.6
Operating Income (Reported)
-
-10.9
1.7
108.5
149.6
Operating Income (Adjusted)
-24.6
-10.9
1.7
119.7
136.1
FY-4FY-3FY-2FY-1FY01234
presentment in Millions except per share data. All rights reserved. Terms Of Use